Legato Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.7M Sell
19,253
-6,793
-26% -$705K 0.15% 210
2026
Q2
$2.54M Buy
26,046
+13,514
+108% +$1.18M 0.21% 148
2026
Q1
$1.05M Buy
+12,532
New +$726K 0.1% 282

Other funds holding DNTH

Legato Capital Management's DNTH Position: Q3 2026 in Review

Legato Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 26% in Q3 2026, selling an estimated $705K and leaving 19,253 shares worth $1.7M. The position accounts for 0.15% of the portfolio, ranked #210.

Legato Capital Management first reported a position in DNTH in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.54M in Q2 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Legato Capital Management held 19,253 shares of Dianthus Therapeutics worth $1.7M as of Q3 2026.
  • Legato Capital Management sold 6,793 Dianthus Therapeutics shares in Q3 2026, an estimated $705K.
  • Dianthus Therapeutics made up 0.15% of Legato Capital Management's portfolio in Q3 2026, its #210 holding.
  • Legato Capital Management first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Legato Capital Management's Dianthus Therapeutics position peaked at $2.54M in Q2 2026.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Legato Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.